Disopyramide

Home
About
Help
History (1)
- Disopyramide
- See All Pages

"Disopyramide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

Descriptor ID	D004206
MeSH Number(s)	D03.383.725.227
Concept/Terms	Disopyramide Disopyramide Diisopyramide Disopyramide Phosphate Disopyramide Phosphate Disopyramide Phosphate (1:1) Disopyramide Phosphate (1:1), (+-)-Isomer Disopyramide Phosphate (1:1), (+-)-Isomer Disopyramide Phosphate (1:1), (R)-Isomer Disopyramide Phosphate (1:1), (R)-Isomer Disopyramide Phosphate (1:1), (S)-Isomer Disopyramide Phosphate (1:1), (S)-Isomer Disopyramide, (+-)-Isomer Disopyramide, (+-)-Isomer Disopyramide, (R)-Isomer Disopyramide, (R)-Isomer Disopyramide, (S)-Isomer Disopyramide, (S)-Isomer Disopyramide, D-Tartrate (1:1), (S)-Isomer Disopyramide, D-Tartrate (1:1), (S)-Isomer Disopyramide, L-Tartrate (1:1), (R)-Isomer Disopyramide, L-Tartrate (1:1), (R)-Isomer Disopyramide, L-Tartrate (1:1), (S)-Isomer Disopyramide, L-Tartrate (1:1), (S)-Isomer Disopyramide, L-Tartrate (1:2), (+-)-Isomer Disopyramide, L-Tartrate (1:2), (+-)-Isomer Disopyramide, L-Tartrate, (S)-isomer Disopyramide, L-Tartrate, (S)-isomer Norpace Norpace Palpitin Palpitin Palpitine Rhythmodan Rhythmodan Ritmilen Ritmilen Rythmilen SC-13957 SC-13957 SC 13957 SC13957 Disopyramide Monohydrochloride Disopyramide Monohydrochloride

Below are MeSH descriptors whose meaning is more general than "Disopyramide".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Pyridines [D03.383.725]
Disopyramide [D03.383.725.227]

Below are MeSH descriptors whose meaning is more specific than "Disopyramide".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Disopyramide" by people in this website by year, and whether "Disopyramide" was a major or minor topic of these publications.

Bar chart showing 5 publications over 5 distinct years, with a maximum of 1 publications in 2005 and 2020 and 2023 and 2024 and 2025

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	1	0	1
2020	0	1	1
2023	0	1	1
2024	0	1	1
2025	1	0	1

Below are the most recent publications written about "Disopyramide" by people in Profiles.

Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.

View in: PubMed
Masri A, Choudhury L, Barriales-Villa R, Elliott P, Maron MS, Nassif ME, Oreziak A, Owens AT, Saberi S, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Nagueh SF, Wang A, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Sherrid MV, Abraham TP. Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM. J Am Coll Cardiol. 2024 Nov 05; 84(19):1839-1849.

View in: PubMed
Owens AT, Masri A, Abraham TP, Choudhury L, Rader F, Symanski JD, Turer AT, Wong TC, Tower-Rader A, Coats CJ, Fifer MA, Olivotto I, Solomon SD, Watkins HC, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn R, Wohltman A, Maron MS. Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3. J Card Fail. 2023 11; 29(11):1576-1582.

View in: PubMed
Rowin EJ, Sridharan A, Madias C, Firely C, Koethe B, Link MS, Maron MS, Maron BJ. Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 08 01; 128:75-83.

View in: PubMed
Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005 Apr 19; 45(8):1251-8.

View in: PubMed
Ellrodt G, Singh BN. Adverse effects of disopyramide (Norpace): toxic interactions with other antiarrhythmic agents. Heart Lung. 1980 May-Jun; 9(3):469-74.

View in: PubMed

People

Explore

Similar Concepts

Top Journals